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Abstract
The transforming growth factor b (TGFb) superfamily of signal transduction molecules plays crucial roles in the regulation of
cell behavior. TGFb regulates gene transcription through Smad proteins and signals via non-Smad pathways. The TGFb
pathway is strictly regulated, and perturbations lead to tumorigenesis. Several pathway components are known to be targeted
for proteasomal degradation via ubiquitination by E3 ligases. Smurfs are well known negative regulators of TGFb, which
function as E3 ligases recruited by adaptors such as I-Smads. TGFb signaling can also be enhanced by E3 ligases, such as
Arkadia, that target repressors for degradation. It is becoming clear that E3 ligases often target multiple pathways, thereby
acting as mediators of signaling cross-talk. Regulation via ubiquitination involves a complex network of E3 ligases, adaptor
proteins, and deubiquitinating enzymes (DUBs), the last-mentioned acting by removing ubiquitin from its targets. Interest-
ingly, also non-degradative ubiquitin modiﬁcations are known to play important roles in TGFb signaling. Ubiquitin
modiﬁcations thus play a key role in TGFb signal transduction, and in this review we provide an overview of known players,
focusing on recent advances.
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Introduction
One of the major regulators of cell communication in
all multicellular organisms is transforming growth
factor b (TGFb). TGFb is the prototypic family
member of 33 secreted, structurally related human
cytokines. They are involved in the regulation of cell
proliferation, differentiation, apoptosis, and motility
of diverse cell types. Whereas practically all human
cell types respond to TGFb, the actions of certain
family members are more cell type-selective. The
importance of proper TGFb signaling is highlighted
by the observation that perturbed TGFb signaling
results in tumorigenesis, and many different muta-
tions or other alterations in TGFb signaling compo-
nents have been identiﬁed in human cancers.
Intriguingly, TGFb plays a dual role in cancer devel-
opment and progression. During the early stages of
tumorigenesis, TGFb acts as a tumor-suppressor by
inhibiting proliferation. Later in cancer progression,
TGFb has pro-angiogenic and immunosuppressive
effects, and it promotes metastasis by inducing epi-
thelial to mesenchymal transition (EMT). Cancer
cells that manage to evade the anti-proliferative effects
of TGFb and simultaneously maintain the tumor-
promoting effects beneﬁt from this distorted signal-
ing. The wide variation in cellular responses to TGFb
demonstrates the complexity of the intracellular sig-
naling pathways. By studying TGFb signaling and its
cross-talk to other pathways, we gain insight into the
regulation of cell behavior and consequently in the
mechanisms underlying cancer development. In this
review we will focus on the regulation of TGFb
signaling by the ubiquitin system. We will discuss
several mechanisms by which TGFb pathway com-
ponents are targeted for degradation as a way of
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enhanced via the degradation of negative regulators,
and ubiquitination even plays a crucial part down-
stream of TGFb in various cross-talk pathways.
Furthermore, the roles of deubiquitination and non-
degradative ubiquitination will be discussed. Finally,
we will touch upon the opportunities these regulatory
mechanisms give us for pharmacological intervention.
Transforming growth factor b signaling
The TGFb family of cytokines consists of many mem-
bers including bone morphogenetic proteins (BMPs),
growth and differentiation factors (GDFs), and activins.
TGFb ligands signal through receptors and Smads and
regulate target gene transcription (Figure 1). The dif-
ferential expression of co-activators and co-repressors in
the various cell types gives rise to the wide range in
cellular responses. Besides regulating gene transcription
through Smad signaling,TGFb can alsoactivate various
non-Smad pathways (1,2). Some of these pathways
operate independently of Smads; yet others co-operate
or even interfere with Smad signaling. The p38 and Jun
N-terminal kinase (JNK) mitogen-activated protein
(MAP) kinase pathway is activated upon TGFb stim-
ulation via the ubiquitin ligase tumor necrosis factor
(TNF) receptor-associated factor 6 (TRAF6) and
TGFb activated kinase 1 (TAK1). TGFb can also
activate the Ras-Erk-MAPK pathway, depending on
cellular context. This pathway stimulates TGFb-
induced EMT, yet it competes with Smad-dependent
signaling in regulating cell proliferation. Other pathways
affected by TGFb include RhoA-Rock and the phos-
phoinositide 3-kinase (PI3K)-Akt pathway.
Since TGFb signaling is important for a wide
variety of cell functions, it must itself be tightly
regulated. It cannot simply be regarded as an on/
off switch, because both signal strength and duration
are important factors affecting the cellular response
outcome. The cellular response to TGFb is highly
dependent on the expression levels of receptors (3),
Smads, transcription factors, and other signal regu-
lators. Phosphorylation is an important modiﬁcation
insignalingpathways;thereforedephosphorylationis
involved in regulating signal transduction as well.
And ﬁnally, as the abundance of speciﬁcp r o t e i n s
and the half-life of activated signaling molecules
are crucial for determining the response, targeted
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Figure 1. The transforming growth factor b (TGFb)p a t h w a y .T G F b ligands function as dimers and signal through type I and type II
serine/threonine kinase receptors. Upon ligand binding, the receptors form heterotetrameric complexes allowing the type II receptors to
phosphorylate and activate the type I receptors. Subsequently, receptor-activated Smads (R-Smads) are recruited to the type I receptors
and phosphorylated. The activated R-Smads associate with the Co-Smad, Smad4, and this heteromeric complex translocates to the
nucleus to participate in the transcriptional control of speciﬁc target genes (94). TGFb can also activate various non-Smad signaling
pathways.
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cell sensitivity and signal duration. A major pathway
to achieve this is the ubiquitin-proteasome system.
The ubiquitin system
Ubiquitination is a post-translational modiﬁcation of
proteins, which can affect their stability, activity, and
cellular localization. Ubiquitin (Ub) is a small,
8.5 kDa, protein that is conjugated onto target proteins
via its C-terminal glycine (Gly76) residue. Ub is pro-
duced in a precursor state of linear chains of Ub
moieties or fused to ribosomal proteins. The activity
of deubiquitinating enzymes (DUBs) is required to
produce free Ub, either by processing precursor Ub
or by recycling Ub by removing it from its targets (4).
The activity of E1 activating enzymes, E2 conjugating
enzymes, and E3 ubiquitin ligases is necessary to
conjugate ubiquitin onto its substrates (5). Functional
differences between the many different E2 and
E3 enzymes lead to substrate and chain speciﬁcity.
Ub can be conjugated as a single moiety (mono-ubi-
quitination), or it can form chains, using all internal
lysines (K), including K11, K48, and K63 (Figure 2),
or a head-to-tail linear chain. All ubiquitin chains, with
the exception of K63 chains, have been described to
target proteins for proteasomal degradation, thereby
regulating their stability. Furthermore, linkage-
speciﬁc ubiquitin chains have been shown to affect
protein–protein interactions and can thereby regulate
protein function (6).
E3 ligases display both substrate and chain speci-
ﬁcity. While one E3 ligase may preferentially target its
substrates for degradation via K48 Ub chains, another
may regulate the localization of its targets via mono-
ubiquitination. Directly opposing the conjugating
function of E3 ligases are the deubiquitinating
enzymes (DUBs). DUBs are proteases that remove
Ub moieties from their targets. In case of the K48 Ub
chain-mediated proteasomal degradation pathway,
DUBs remove the Ub chain and stabilize the protein.
DUBs also show substrate and chain speciﬁcity and
therefore represent another layer of regulation of the
ubiquitin system.
Negative regulation of TGFb signaling by the
ubiquitin-proteasome system
TGFb induces the expression of various genes,
among which are negative regulators, such as I-Smads
(7,8) and Smurfs that function in a feedback mech-
anism. Smurfs are HECT (homologous to the E6-
accessory protein C-terminus)-type E3 ligases that are
known regulators of the TGFb pathway. E3 ligases
regulate their own abundance via autoubiquitination.
Under steady-state conditions, Smurf2 inhibits its
own ubiquitinase activity and is thereby stabilized
(9). Upon binding of Smad7, Smurf2 becomes acti-
vated. When TGFb signaling is active, interacting
Smurfs and I-Smads are exported from the nucleus
to the cytoplasm. I-Smads recruit Smurfs to the active
TGFb receptor complexes, and Smurfs target the
complexes for degradation (10–12). CD109 has
recently been identiﬁed as a negative regulator of
TGFb signaling by enhancing receptor ubiquitina-
tion, in a ligand-dependent manner, by Smurf2 and
Smad7 (13,14). The E3 ligases WWP1 (WW domain-
containing protein 1) and NEDD4-2 (neural precur-
sor cell expressed, developmentally down-regulated
4–2) have also been shown to be recruited to TGFb
receptor complexes by Smad7 (15,16). The subse-
quent ubiquitination and degradation of the receptors
leads to an inhibition of all downstream pathways.
Smurfs also regulate the canonical TGFb pathway at
the level of Smad signaling. Smurf1 was shown to ubi-
quitinate Smad1 and Smad5 (11,17), while Smurf2
ubiquitinates Smad1 and Smad2 under steady-state
conditions (18,19). The abundance of Smad1 and
Smad3 is also regulated by the E3 Ub ligase U-box-
containing carboxyl terminus of Hsc70-interacting pro-
tein (CHIP) (20,21). For Smad3, it was shown that a
complex of Axin and glycogen synthase 3-b (GSK3b)
affects the ubiquitination, thereby linking R-Smad levels
to other cellular pathways in which Axin/GSK3b func-
tion (22). These ubiquitin-mediated degradation path-
ways are important for controlling the sensitivity of the
cell to TGFb by adjusting the absolute and relative
abundance of different Smads before the initiation of
signaling.
In the presence of TGFb, the active receptor com-
plexes phosphorylate R-Smads, which signal in the
nucleus. To limit signaling by Smad complexes, the
phosphorylation of R-Smads increases their suscepti-
bility to ubiquitination by E3 ligases such as Smurfs.
Phosphorylated Smad1 is subsequently phosphory-
lated by MAP kinase and GSK3b (23) to increase
its ubiquitination by Smurf1. Also Smad2 becomes
more susceptible to ubiquitination by Smurf2 after
phosphorylation. Pin1 interacts with phosphorylated
Smad2 and Smad3 and enhances their ubiquitination
by Smurf2 (24). Phospho-Smad2/3 are also targeted
for degradation by NEDD4L (25). Furthermore,
Smad3 is targeted for degradation by ROC1-
SCF
Fbw1a, and this is dependent on TGFb (26). In
the nucleus, R-Smads are phosphorylated by CDK8
and CDK9 to enhance transcription, yet these mod-
iﬁcations increase Smad ubiquitination (27). The sub-
sequent phosphorylations on activated R-Smads by
several kinases regulate the afﬁnity for E3 ligases and
thereforethehalf-lifeofactivatedSmads (28).E3ligase
Ubiquitin in TGFb signaling 155Arkadia was shown to ubiquitinate phospho-Smad2/3,
even though Arkadia is generally regarded as a positive
regulator of TGFb signaling (see below). Phospho-
Smad2/3 are polyubiquitinated by Arkadia after the
initiationoftargetgenetranscription,andthereforethis
ubiquitination step may function to efﬁciently termi-
nate signaling (29).
The Co-Smad, Smad4, is required for Smad-
mediated transcriptional control. By regulating the
availability of Smad4, the intracellular response to
TGFb and BMP can be controlled. Various E3 Ub
ligases have been identiﬁed that target Smad4 for deg-
radation. Similar to R-Smads, Smad4 can be ubiquiti-
nated by Smurfs, WWP1, and NEDD4-2 recruited by
Smad7(30).BindingofJab1inducestheubiquitination
anddegradationofSmad4(31).CHIPandSCF
b-TrCp1
can also conjugate poly-ubiquitin chains onto Smad4,
which leads to its degradation and an inhibition of
signaling (32,33). The importance of proper regulation
of the ubiquitin-mediated proteasomal degradation of
Smad4 becomes clear in many human cancers where
Smad4isoftenlost.Mutations in Smad4canleadtoan
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Figure 2. Theubiquitin system. A: Freeubiquitinis boundbythe active cysteineresidueof an E1 ubiquitin-activating enzyme,and this process
requires ATP. Next, Ub is transferred onto the active cysteine of an E2 ubiquitin-conjugating enzyme. Finally, Ub is transferred onto a lysine
residue of the target protein by an E3 ubiquitin ligase. Ubiquitin can be conjugated as mono-ubiquitin (B) or in chains such as K63 chains (C)
or K48 chains (D), the last-mentioned known for targeting substrates for proteasomal degradation.
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protein unstable (34,35).
As TGFb signaling progresses, the expression of
many negative regulators, such as Smurfs, is induced,
and higher protein levels of these E3 ligases increase
the degradation rate of the receptors and Smads,
thereby terminating signaling. Yet the ubiquitin sys-
tem is also an ideal mediator of cross-talk between
signaling pathways. Different signals induce the
expression of I-Smads and thereby inhibit TGFb
signaling, but pathways can also modulate TGFb
signaling directly by recruiting the ubiquitin system.
Estrogen was shown to inhibit TGFb signaling by
promoting proteasomal degradation of Smad2/3 by
Smurf1. Estrogen receptor a directly recruits Smurf
to Smads, and this pathway represents direct inhib-
itory cross-talk mediated by ubiquitin protein modi-
ﬁcation (36).
Positive regulation of TGFb signaling by the
ubiquitin-proteasome system
An important E3 ligase for the enhancement of TGFb
signaling is Arkadia. Arkadia was identiﬁed as a positive
regulator of Nodal signaling, a TGFb family member.
Arkadia targets its substrates for proteasomal degrada-
tion. Known targets for Arkadia include Smad7 (37),
c-Ski, and SnoN (38), all negative regulators of TGFb
signaling (Figure 3). Smad7 was already described to
recruit various E3 ligases to the TGFb receptors and
Smads, yet it also inhibits TGFb signaling directly by
inhibiting the interaction of R-Smads with the receptor
complexes (7). C-Ski and SnoN inhibit Smad signaling
in the nucleus by disrupting the interaction of Smads
with transcriptional co-activators and by inducing inac-
tivation of Smad complexes (39,40). They are also
responsible for repressing transcription in the absence
of TGFb (41). Upon TGFb signaling, phospho-Smads
translocate into the nucleus and recruit Arkadia, but
also other E3 ligases such as Smurf2 (42) and anaphase-
promoting complex (APC) (43), to induce the ubiqui-
tination of c-Ski and SnoN. The ubiquitination of
c-Ski was found to be enhanced by the association of
RB1-inducible coiled-coil 1 (RB1CC1) with Arkadia
(44).The degradation ofSmad7by Arkadiaisenhanced
byAxin,a scaffold protein known for its function in Wnt
signaling. Wnt negatively regulates Axin, thereby also
inhibiting the ubiquitination of Smad7 and thus impact-
ing TGFb signaling (45). By ubiquitinating negative
regulators, Arkadia stimulates TGFb signaling.
More examples of positive regulation of TGFb
signaling via proteasomal degradation of negative
regulators have been identiﬁed. TGFb-induced factor
1 (TGIF1) is a transcriptional repressor of TGFb
signaling. Phosphorylated TGIF1 was found to be
targeted for degradation by Fbxw7. Fbxw7 is the
substrate recognition component of a ubiquitin ligase
complex which was found to target proteins such as
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Figure 3. Positive regulation of TGFb signaling by Arkadia. TGFb signaling is inhibited by I-Smads, in co-operation with various E3 ligases,
targeting several components among which the receptor complexes. SnoN and c-Ski inhibit TGFb signaling at a later step by acting as
transcriptional co-repressors. Arkadia targets I-Smad (Smad7), SnoN, and c-Ski for degradation, thereby positively regulating signaling.
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Fbxw7 stimulates TGFb signaling by inducing the
degradation of TGIF1 (46).
Another E3 ligase involved in TGFb regulation is
WWP2. The full-length WWP2 (WWP2-FL) was
shown to ubiquitinate both Smad2/3 and Smad7.
Interestingly, the WWP2-N isoform stimulates the deg-
radation of Smad2/3, yet the WWP-C isoform and
WWP2-FL preferentially ubiquitinate Smad7 after
TGFb stimulation. These ﬁndings imply that depend-
ing on the speciﬁc isoforms expressed, TGFb signaling
can be either activated or inhibited (47).
Ubiquitin as a mediator of non-Smad signaling
TGFb exerts its effects via Smad-dependent and
independent pathways. Some of the downstream
functions of TGFb signaling are dependent on the
ubiquitin system. TGFb was recently found to induce
the ubiquitination and subsequent proteasomal deg-
radation of Krüppel-like factor 4 (KLF4). KLF4 is a
transcription factor involved in the regulation of core
cell functions such as proliferation, differentiation,
and apoptosis, and it has been implicated in carcino-
genesis. TGFb signaling induces the ubiquitination of
KLF4 by Cdh1/APC, and this pathway is important
for TGFb-mediated transcription regulation (48).
Besides its function in regulating protein levels of
TGFb signaling components, Smurf1 has also been
shown to function downstream of TGFb as a regulator
of RhoA signaling (49). TGFb is known to affect the
RhoA pathway, and this is important for TGFb-
induced EMT. Activated TbRII phosphorylates Par6,
whichtheninteractswithSmurf1.Smurf1subsequently
targets RhoA for degradation, and this loss of RhoA
leads to hallmarks of EMT, such as the loss of tight
junctions and cell polarity (50). Furthermore, Smurf1
was shown to be phosphorylated, thereby its substrate
preference switched from Par6 to RhoA (51). The
importance of Smurfs in the regulation of cell polarity,
involving Par6 and a non-canonical Wnt pathway, is
becoming increasingly clear (52,53).
Smurfs also mediate TGFb anti-inﬂammatory sig-
nals together with Smad6 by targeting MyD88 for
degradation (54). Smurf1 has been implicated in the
regulation of inﬂammation due to its ability to ubi-
quitinate TNF receptor associated factors (TRAFs)
(55,56). Smurf2 was found to associate with TRAF2
and ubiquitinate TNF receptor 2, thereby affecting
downstream signaling (57). It is becoming clear that
E3 ligases such as Smurfs do not just regulate a single
pathway; rather they function as the effectors of
various types of regulation, depending on their
recruitment by other proteins. Together with I-Smads
they inhibit the TGFb pathway, yet other adaptors
may recruit them to other pathways, such as RhoA
and TRAFs. The substrate speciﬁcity of E3 ligases,
such as Smurf1, can be regulated by post-translational
modiﬁcations and cellular localization (51,58).
A single E3 ligase can therefore have different func-
tions depending on cellular context.
Role of DUBs in TGFb signaling
DUBs remove Ub chains or mono-ubiquitin modiﬁca-
tions from target proteins, thereby counteracting the
function of E3 ligases. They show speciﬁcity for the
type of Ub modiﬁcation and the substrate, yet generally
they are less speciﬁct h a nE 3l i g a s e s .S o m eD U B sh a v e
been identiﬁed to target components of the TGFb path-
way.OnesuchDUBisUCH37,whichwasshowntobind
to Smad7 and deubiquitinate TbRI (59). It stabilizes the
type I receptor and can therefore be regarded as the
counterpart of E3 ligases such as Smurfs in regulating
TGFb receptor expression. UCH37 enhances early sig-
naling and is important for TGFb-induced migration
(60). CYLD was shown to be involved in the regulation
of TGFb signaling in T cells. CYLD is a DUB that
preferentially hydrolyses K63 chains and is known to
inhibit JNK and NF-kB signaling. CYLD deubiquiti-
nates Smad7 and thereby inhibits the activation ofTAK1
andp38,thusinhibitingtheTGFb-induceddevelopment
ofregulatoryTcells(61).Recently,USP15wasshownto
deubiquitinate mono-ubiquitinated R-Smads (62). The
mono-ubiquitination of R-Smads inhibits DNAbinding,
therefore USP15 is required for proper TGFb signaling.
Two other DUBs that have been implicated in
TGFb signal transduction are AMSH, associated
molecule with the SH3 (Src homology 3) domain
of SA (signal-transducing adaptor molecule) (63),
and AMSH-like protein (AMSH-LP). They were
shown to associate with I-Smads and inhibit their
function, thereby potentiating BMP and TGFb sig-
naling (64,65). Furthermore, AMSH was shown to be
ubiquitinated by Smurf2 via RNF11 recruitment
(66). These DUBs preferentially cleave K63-linked
Ub chains (67), yet this DUB activity has not been
conﬁrmed to be necessary for affecting TGFb signal-
ing. AMSH has been described to function in the
regulation of receptor turnover by the endosomal
sorting complexes required for transport (ESCRT)
machinery (68). It is unclear what its targets are
precisely, yet a role in receptor trafﬁcking implies a
more general function in cell signaling.
Non-degradative ubiquitin modiﬁcations in
TGFb signaling
As previously discussed, not all forms of ubiquitina-
tion lead to proteasomal degradation of the target
158 M. De Boeck & P. Ten Dijkeprotein. Other types of Ub modiﬁcations, such as
mono-ubiquitination or K11 and K63 chains, serve
to alter the activation state of the protein, its subcel-
lular localization, or its ability to form protein–protein
interactions. In the TGFb signaling pathway various
examples of these types of post-translational modiﬁ-
cations have been identiﬁed, which demonstrate the
biological importance of this ‘alternative side’ of the
ubiquitin system.
Modulating Smad2 phosphorylation
One of the ﬁrst steps in the canonical TGFb pathway
is the phosphorylation of R-Smads by the TbRI. The
efﬁciency of this activation step was shown to be
modulated via ubiquitination. Athophin 1-interacting
protein 4 (AIP4) or Itch was shown to ubiquitinate
Smad2 and thereby promote the phosphorylation of
Smad2 by TbRI. This results in an enhancement of
TGFb signaling (69). E3 ligase Cbl-b is thought to
have a similar function in T cells, since its loss reduces
TGFb-induced Smad2 phosphorylation (70,71).
AIP4/Itch was also shown to bind Smad7 and recruit
it to TbRI, thereby coupling Smad2 phosphorylation
to signal inhibition.
Smad4 mono-ubiquitination
Activated Smad complexes, containing Smad4, trans-
locate to the nucleus and bind to the promoter regions
of target genes. They recruit other factors, such as
histone acetyltransferases (HATs) p300/CBP to the
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Figure 4. Mono-ubiquitination of Smad4. Active complexes of Co-Smad, Smad4, and phosphorylated R-Smads recruit histone acetyltransferases
(HATs)tochromatin.TheacetylationofhistonesrecruitsEctodermin/TIF1g (Ecto),whichthendisruptsSmadcomplexesandmono-ubiquitinatesthe
Co-Smad.ReleasedR-Smadsaremostlikelydephosphorylatedandexportedtothecytoplasm.UbiquitinatedSmad4isexportedtothecytoplasm,where
the deubiquitinating enzyme (DUB) FAM/USP9x removes the ubiquitin moiety. Smad4 is now ready once again to form complexes with R-Smads.
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Figure 5. TRAF6 activates TAK1. Tumor necrosis factor receptor
(TNFR)-associated factor 6 (TRAF6) binds activated TGFb recep-
tor complexes and is activated via K63 autoubiquitination.
TRAF6 subsequently ubiquitinates and activates TGFb-associated
kinase (TAK1), which is responsible for activating non-Smad
pathways such as the p38 MAP kinase pathway.
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Target E3 ligase/ DUB Adaptor Comments References
Negative regulation
TbRI Smurf1 Smad6/7, FKBP12 (10,11,95)
Smurf2 Smad7 (12)
NEDD4-2 Smad7 (16)
WWP1 Smad7 (15)
Smad1/Smad5 Smurf1 LMP-1, Smad6/7 (11,17,96)
Smad1 Smurf2 (19)
CHIP (32)
Smad2 Smurf2 (18,97)
NEDD4-2 (16)
WWP1 TGIF (98)
WWP2-FL WWP2-N
Smad3 CHIP (20)
ROC1-SCF
Fbw1a (26)
WWP2-FL WWP2-N (47)
Smad4 Smurf1, Smurf2, NEDD4-2,
WWP1
Smad2/6/7 (30)
CHIP (32)
SCF
b-TrCp1 (33)
SCF
Skp2 Smad4 mutants (99)
Positive regulation
Smad7 Smurf1/2 Affected by acetylation (10,12,83,85)
Arkadia Axin (37,45)
WWP2-FL, WWP2-C (47)
SnoN Arkadia (38,89)
Smurf2 Smad2 (42)
APC Smad2/3 (43,100)
TGIF Fbxw7 (46)
Examples of ubiquitin-mediated non-Smad signaling
KLF4 Cdh1/APC Induced by TGFb (48)
Par6 Smurf1 (51)
RhoA Smurf1 (50-52,101)
MyD88 Smurf1/2 Smad6 (54)
TRAFs Smurf1 (55,56)
TNFR2 Smurf2 TRAF2 (57)
DUBs in TGFb signaling
TbR1 UCH37 (59,60)
Smad1/2/3 USP15 (62)
Smad6 AMSH Requirement of DUB activity not conﬁrmed (64)
Smad2/7 AMSH-LP Requirement of DUB activity not conﬁrmed (65)
Smad7 CYLD DUB removing K63 (61)
Non-degradative Ub modiﬁcations
Smad2 AIP4/Itch Increased Smad2 phosphorylation (69)
Cbl-b Increased Smad2 phosphorylation. Not conﬁrmed (70,71)
160 M. De Boeck & P. Ten Dijkechromatin to promote transcription. The acetylation
of histones is thought to increase their afﬁnity for
proteins such as Ectodermin/TIF1g, an E3 ligase.
Bound to chromatin, Ectodermin/TIF1g is activated
to mono-ubiquitinate Smad4 at K519, and this
disrupts the association of Smad4 with phospho-
Smad2 (72,73). Mono-ubiquitinated Smad4 is
exported to the cytoplasm (74). FAM/USP9x is a
DUB that counteracts the mono-ubiquitination of
Smad4. FAM/USP9x activity is required for
Smad4-mediated TGFb signaling, because it re-
enables Smad4 to form complexes with R-Smads
and signal in the nucleus (75). This mechanism shows
a feedback loop where active Smad complexes on
chromatin indirectly recruit an E3 ligase to terminate
signaling (Figure 4). Moreover, the duration of Smad-
chromatin binding can be regulated by the efﬁciency
of this system. Inhibition of TGFb signaling by Ecto-
dermin/TIF1g is important in vivo during embryonic
development (72,76).
The role of TRAF6
Tumor necrosis factor receptor (TNFR)-associated
factor 6 (TRAF6) is a ubiquitin E3 ligase, which
preferentially conjugates K63 Ub chains onto its sub-
strates.TRAF6 interacts withTbRIand isactivated via
autoubiquitination, induced by TGFb ligand binding
to the receptors. Active TRAF6 ubiquitinates and
thereby activates TGFb-associated kinase (TAK1),
which is important for the TGFb-induced activation
of the p38 MAP kinase pathway (Figure 5) (77).
TAK1 is ubiquitinated by TRAF6 but also by
TRAF2 in the TNFa pathway. Ubiquitin-speciﬁc
peptidase 4 (USP4) is a DUB for TAK1 and was
found to inhibit TNFa and TGFb-induced NF-kB
activation (78). This mechanism shows how the
ubiquitin system can function in the cross-talk bet-
ween pathways. In cancer cells, TRAF6 was also
shown to ubiquitinate TbRI upon TGFb stimulation.
TbRI is subsequently cleaved by TNFa-converting
enzyme (TACE), and this action creates an intracel-
lular domain of TbRI, which functions in transcrip-
tional complexes in the nucleus to induce the
expression of EMT-related genes such as Snail and
MMP2 (79). These activities of TRAF6 involve the
tumor-promoting arm of TGFb signaling.
Concluding remarks
TGFb is not only regulated via ubiquitination, it also
relies on ubiquitination for its effect on other path-
ways. The ubiquitin system is a major tool for various
pathways to regulate downstream mediators or other
signaling pathways. E3 ligases show target speciﬁcity;
yet their action in vivo is dependent on other proteins
to act as adaptors or activators, and the speciﬁcity of
E3 ligases is also dependent on the E2 enzyme pro-
viding the Ub moiety (5,49). Most E3 ligases dis-
cussed in this review have also been shown to target
components of other signaling pathways.
This review focuses on ubiquitin modiﬁcations, yet
other modiﬁcations such as the conjugation of small
ubiquitin-like modiﬁer (SUMO) onto TGFb signal-
ing components have also been found to be impor-
tant. Both receptors and Smads have been shown to
be SUMOylated, affecting their function (80-82).
Different modiﬁcations, such as phosphorylation,
acetylation, SUMOylation, and ubiquitination, can
affect each other by recruiting enzymes, or they can
compete with each other for binding sites. One clear
example of this interplay between modiﬁcations in
TGFb signaling is the regulation of Smad7 stability.
Smad7 was found to be acetylated by p300 on two
lysine residues (83). These are the same residues
Smurf1 uses to conjugate ubiquitin chains onto
Smad7 to target it for degradation. SIRT1 is a dea-
cetylase that counteracts the acetylation of Smad7,
making the lysine residues available for ubiquitination
(84). Acetylation and ubiquitination thereby compete
in regulating Smad7 stability (85). In summary, the
real story is longer than presented here, and with the
identiﬁcation of new targets, adaptors, and enzymes
the overall picture is becoming increasingly complex.
An overview of ubiquitin modiﬁcations discussed in
this review can be found in Table I.
As disruptions in TGFb signal transduction are
implicated in a wide variety of cancers and the
Table I. (Continued).
Target E3 ligase/ DUB Adaptor Comments References
Smad4 Ectodermin/TIF1g Acetylated histones Mono-Ub disrupting complex with Smad2 (72,75,76)
FAM/USP9x DUB removing mono-Ub (75)
TAK1 TRAF6 K63 activation (77)
USP4 DUB (78)
Ubiquitin in TGFb signaling 161ubiquitin system is important for the regulation of
this pathway, it does not come as a surprise that in
several cancers dysregulations of E3 ligases such as
Smurfs and Arkadia have been found (86,87). In
various tumors, increased Smurf expression leads to
decreased Smad levels, and this affects tumor pro-
gression and correlates with poor prognosis (88).
A loss of Smad4 expression is a common ﬁnding in
many cancers. This loss can be caused by mutations
which make it more prone to ubiquitination, thereby
destabilizing Smad4 (34,35). In some tumors, TGFb
signaling is inhibited by the over-expression of a
transcriptional co-repressor such as SnoN. This
over-expression of SnoN was found to be caused
by a loss of Arkadia and thereby a lack of Arkadia-
mediated SnoN degradation. A restoration of Arkadia
expression rescued TGFb signaling in these cells
(89,90). A loss of Fbxw7 and subsequent increase
in TGIF1 expression has also been implicated in
cancer (46). E3 ligases, and also DUBs (91), therefore
represent a new class of potential oncogenes and
tumor suppressors.
The ubiquitin system can be targeted pharmacolog-
ically at different levels. The only drug now being used
in the clinic is bortezomib, a general proteasome
inhibitor. This drug has cytotoxic effects due to the
non-speciﬁc inhibition of protein degradation. It is
prescribed for multiple myeloma and mantle cell lym-
phoma, and more proteasome inhibitors are currently
under investigation as anti-cancer drugs. Yet the ubi-
quitin system has the potential of providing us with
speciﬁc drug targets (92,93). Small molecule E3 ligase
inhibitors can potentially rescue speciﬁc proteins from
proteasomal degradation. An example currently being
investigated is the E3 ligase MDM2, which targets the
tumorsuppressorp53fordegradation.But alsoSmurfs
are interesting targets, as they are found to be over-
expressed in certain cancers. DUBs are proteases and
are therefore more easily targeted speciﬁcally by inhi-
bitors. Some DUB inhibitors, such as inhibitors of
USP7, are being investigated as anti-cancer drugs.
Small molecule inhibitors targeting E3 ligases or
DUBs involved in the regulation of TGFb signaling
could prove useful in counteracting perturbations in
TGFb signaling commonly found in cancer cells.
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